|Day Low/High||42.09 / 43.28|
|52 Wk Low/High||36.00 / 46.63|
Abbott Laboratories (ABT) stock was increasing Thursday afternoon as Muddy Waters attempts to break up the company's proposed acquisition of St. Jude (STJ).
Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:
Abbott Laboratories (ABT) has great growth prospects and has paid increasing dividends for more than 40 years. Here's why this Dividend Aristocrat should be in your investment portfolio.
Abbott Laboratories (ABT) said Alere (ALR) hasn't disclosed key information, making the company question whether its proposed $5.8 billion deal will close.
Insiders at these companies have been scooping up shares of their own stock lately.
TheStreet highlights 3 stocks pushing the health services industry higher today.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #84 spot from Simon Property Group, Inc. , according to ETF Channel.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Abbott’s (ABT) stock price target was increased to $50 from $48 at Barclays following the company’s 2016 second quarter results.
The medical device company has two pending acquisitions worth just under $40 billion combined.
The company reported flat but in line earnings of $1.06 per share.
Abbott Labs (ABT) 2016 second quarter results surpassed analysts’ expectations.
Trade-Ideas LLC identified Abbott Laboratories (ABT) as a post-market leader candidate
Abbott Labs (ABT) will report 2016 second quarter earnings on Wednesday, July 20 before the market opens.
Abbott Labs -- with its 2.5% dividend yield and market underperformance -- will look safer when the market begins to rotate out of hotter stocks.
Can medical technology stocks continue their momentum higher in the second half of the year? Investors say yes, but technical analysis says not necessarily.
Abbott Labs (ABT) is scheduled to report 2016 second-quarter financial results before the market open on Wednesday.
Jim Cramer will be watching a host of earnings next week. In addition, he offers his playbook for financial literacy.
Wedbush analyst Tao Levy also does not expect to see rival offers to emerge for St. Jude Medical.
- Approval includes Toric version of Symfony IOL for people with astigmatism
TheStreet highlights 3 stocks pushing the health services industry lower today.
Abbott Labs (ABT) absorbable stent, which was approved by the FDA last week, has gone into its first patients.
Oil began to rebound Wednesday from steep declines earlier this week.